厄妥索单抗由于费森尤斯开发计划的改变,评估乳癌治疗的II期临床试验被终止。(以便他们可以专注于其他产品如卡妥索单抗(英语:catumaxomab)(商品名Removab)。) Kiewe, Philipp; Thiel, Eckhard. Ertumaxomab: a trifunctional
单克隆抗体命名法 Lordick, F.; Ott, K.; Weitz, J.; Jäger, D. The evolving role of catumaxomab in gastric cancer. Expert Opinion on Biological Therapy. 2008, 8 (9):